A federal judge has declined to dismiss claims that Johnson & Johnson is unfairly suppressing competition of its anti-inflammatory drug Remicade.

U.S. District Judge J. Curtis Joyner of the Eastern District of Pennsylvania on Aug. 10 declined to grant J&J’s motion to dismiss the lawsuit Pfizer v. Johnson & Johnson. The ruling allows Pfizer to proceed with the antitrust lawsuit it brought against J&J on allegations that rebate programs J&J entered into with insurers and hospitals were designed to curb competition with Pfizer’s biosimilar anti-inflammatory medication called Inflectra.